Autoantibodies as predictors of biological therapy for early rheumatoid arthritis


Autoria(s): MOTA, Licia Maria Henrique da; SANTOS NETO, Leopoldo Luiz dos; PEREIRA, Ivanio Alves; BURLINGAME, Rufus; MENARD, Henri A.; LAURINDO, Ieda Maria Magalhaes
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Introduction: The association between serological markers with the need of biological therapy for early rheumatoid arthritis (ERA) is not known, with few available data addressing this question. Objectives: To prospectively evaluate a cohort of patients with ERA (less than 12 months of symptoms) in order to determine the possible association between serological markers (rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP), and citrullinated anti-vimentin (anti-Sa) with parameters of therapeutic outcome (this later defined by the need of introducing biological therapy). Patients and methods: Forty patients with early RA were evaluated at the time of diagnosis and have been followed for 3 years, in use of standardized therapeutic treatment. Demographic and clinical data were recorded, as well as serology tests (ELISA) for RF (IgM, IgG and IgA), anti-CCP (CCP2, CCP3 and CCP3.1) and anti-Sa in the initial evaluation and at 3, 6, 12, 18, 24 and 36 months of follow-up. As outcomes of the RA development, the need or not for biological therapy during the follow-up period were considered. Comparisons were made through the Student t test, mixed-effects regression analysis and analysis of variance (significance level of 5%). Results: The mean age was 45 (+/- 12) years; a female predominance was observed (90%). At the time of diagnosis, RF was observed in 50% of cases (RF IgA - 42%, RF IgG - 30% and RF IgM - 50%), anti-CCP in 50% (no difference between CCP2, CCP3 and CCP3. 1) and anti-Sa in 10%. After 3 years, no change in the RF prevalence neither in the anti-CCP was observed, but the anti-Sa increased to 17.5% (p = 0.001). Biological therapy was necessary in 22.5% of patients. The mean RF IgA and anti-CCP 2 levels during the 3 years were higher among patients who needed biological therapy (p <0.05 for both). Conclusion: Higher titles of RF and anti-CCP over time were associated with the need for biological therapy.

Identificador

ACTA REUMATOLOGICA PORTUGUESA, v.35, n.2, p.156-166, 2010

0303-464X

http://producao.usp.br/handle/BDPI/23087

http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000280860400006&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord

Idioma(s)

por

Publicador

MEDFARMA-EDICOES MEDICAS, LDA

Relação

Acta Reumatologica Portuguesa

Direitos

restrictedAccess

Copyright MEDFARMA-EDICOES MEDICAS, LDA

Palavras-Chave #Early Rheumatoid Arthritis #Rheumatoid Factor #Anti-cyclic Citrullinated Peptide Antibodies (anti-CCP) #Citrullinated Anti-vimentin (anti-Sa) #Biological Therapy #CYCLIC CITRULLINATED PEPTIDE #INFLIXIMAB TREATMENT #ANTIBODIES #Rheumatology
Tipo

article

original article

publishedVersion